|
Higher Baseline Integrin Beta-1 Level Associated with Possible Increase in the Remission of Steroid-Resistant Nephrotic Syndrome Using Cyclophosphamide Treatment
|
|
| Author:
|
DEDI RACHMADI, AHMEDZ WIDIASTA, CARLA PUSPARANI, KURNIA WAHYUDI, HUSNA NUGRAHAPRAJA, YUNIA SRIBUDIANI
|
| Abstract:
|
Background: Current paradigm regarding the pathogenesis of nephrotic syndrome is evolving around
podocytopathy. Meanwhile, integrin ß1 (ITGB1) has a crucial role in kidney development as it is highly
expressed in the glomerulus and tubules. The purpose of this study is to determine the relationship between
baseline ITGB1 level and the remission of steroid-resistant nephrotic syndrome (SRNS) among children
treated with cyclophosphamide (CPA).
Material and methods: This is a cohort-prospective study in which 81 children with SRNS received
intravenous cyclophosphamide (CPA) at dose of 500 mg/m2 body surface area (BSA) monthly for six months at
Hasan Sadikin Hospital between October 2019 and May 2020. The occurrence of SRNS as a result of systemic
or autoimmun diseases was not included. Furthermore, TGB1 level was measured with enzyme-linked
immunosorbent assay prior to the first CPA administration. Logistics regression model
was applied to the complete remission (CR) data after a successful six month interval, with
remission as the outcome variable (full vs partial), and log ITGB1 as predictors. In silico analysis using
Genemania was conducted in analyzing ITGB1 interaction with other SRNS essential genes.
Results: Thirty nine patients ( 48.1%) had severe proteinuria before CPA administration, while 38 (46.9%) had
negative proteinuria after administration. After controlling for gender and CPA responders, a significant
association was observed between ITGB1 and complete remission (adjusted-OR = 2.12, 95% CI (1.22, 4.06), p
= 0.013).
Conclusion: Based on results and discussion, higher baseline ITGB1 level was associated with increased
remission probability of SRNS in treated CPA children.
|
| Keyword:
|
integrin beta-1; steroid-resistant nephrotic syndrome; proteinuria; cyclophosphamide; remission.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2021.13.02.517
|
| Download:
|
Request For Article
|
|
|